Compare

Dottikon ES Holding AG/€DESN

1D1W1M3M6MYTD1Y5YMAX

About Dottikon ES Holding AG

Dottikon ES Holding AG is a Switzerland-based company specializing in the production of high-quality performance chemicals for the pharmaceutical and chemical industries. It primarily focuses on hazardous chemical reactions, leveraging its expertise in safety and reliability to deliver a range of active pharmaceutical ingredients (APIs) and intermediates. Founded in 1913, the company has a long-standing presence in the chemical industry. Headquartered in Dottikon, Switzerland, the company strategically emphasizes its capabilities in complex chemical processes to serve a global clientele. Dottikon's operations are supported by its state-of-the-art facilities which enable it to handle chemically intensive processes efficiently and safely.
Ticker
€DESN
Sector
Health
Primary listing
XGAT
Employees
900
Headquarters
Dottikon, Switzerland
Website
dottikon.com

DESN Metrics

BasicAdvanced
€4.2B
36.92
€8.19
0.94
-

Bulls say / Bears say

FY 2025/26 sales rose 11.2% to CHF 428.4 million, while operating cash flow increased 19.8% to CHF 114.6 million. That gives Dottikon a stronger cash base as it brings new facilities into use. (MarketScreener)
Recent investment has added large-scale multipurpose production and API-drying capacity, including a newly inaugurated plant. If customer demand fills these facilities, Dottikon has more room to grow without relying only on its existing production footprint. (MarketScreener, Aargauer Zeitung)
The ZKB forecast sales growth of 22.8% in 2026/27 and 27.5% in 2027/28, with new plants expected to support a step-up in production. That points to substantial upside if the ramp-up and customer demand meet expectations. (cash)
Profitability weakened despite higher sales: the EBITDA margin fell to 34.6% from 36.5%, EBIT declined 1.4% and net income fell 1.9%. Higher staffing and materials costs, plus depreciation on new facilities, weighed on results. (MarketScreener)
Dottikon has struggled to find enough engineers to support its expansion, and management said a planned pilot plant was put on hold for lack of staff. That could slow the conversion of investment into usable capacity and sales. (Aargauer Zeitung)
The company warned that tight biotech funding, drug-price regulation, tariffs and geopolitical risks could delay drug development and launches, reducing demand for development projects. This adds uncertainty to the orders needed to fill its expanded facilities. (MarketScreener)
Data summarised monthly by Lightyear AI. Last updated on 14 Oct 2026.

Funds containing DESN

AllUSDEURGBP
Funds
Fund name
Fund size
€DESN weighting
Xtrackers MSCI Europe Small Cap£XXSC
$3.6B0.06%
Xtrackers MSCI Europe Small Cap€DX2J
$3.6B0.06%
Vanguard ESG Developed Europe All Cap£V3EA
€125M0.01%
Vanguard ESG Developed Europe All Cap£V3EL
€35M0.01%
Xtrackers MSCI World Small Cap$XSWC
$183M0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.